Mary Anne Fallon

2.6k total citations · 2 hit papers
15 papers, 2.0k citations indexed

About

Mary Anne Fallon is a scholar working on Oncology, Orthopedics and Sports Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Anne Fallon has authored 15 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Orthopedics and Sports Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Anne Fallon's work include Bone health and treatments (9 papers), Bone health and osteoporosis research (7 papers) and Prostate Cancer Treatment and Research (6 papers). Mary Anne Fallon is often cited by papers focused on Bone health and treatments (9 papers), Bone health and osteoporosis research (7 papers) and Prostate Cancer Treatment and Research (6 papers). Mary Anne Fallon collaborates with scholars based in United States, Germany and Brazil. Mary Anne Fallon's co-authors include Joel S. Finkelstein, Francis J. McGovern, Philip W. Kantoff, Anthony L. Zietman, David Schoenfeld, Matthew R. Smith, Hang Lee, Matthew R. Smith, Matthew Smith and Ivor S. Douglas and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mary Anne Fallon

15 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer

2001 542 citations Matthew R. Smith, Francis J. McGovern et al. New England Journal of Medicine profile →
Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer

2002 520 citations Matthew R. Smith, Joel S. Finkelstein et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers

Countries citing papers authored by Mary Anne Fallon

Since Specialization

Citations

This map shows the geographic impact of Mary Anne Fallon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Anne Fallon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Anne Fallon more than expected).

Fields of papers citing papers by Mary Anne Fallon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Anne Fallon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Anne Fallon. The network helps show where Mary Anne Fallon may publish in the future.

Co-authorship network of co-authors of Mary Anne Fallon

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Anne Fallon. A scholar is included among the top collaborators of Mary Anne Fallon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Anne Fallon. Mary Anne Fallon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer 2008 ·Cancer ·Matthew R. Smith, Hang Lee, Francis J. McGovern, Mary Anne Fallon, (unknown), Anthony L. Zietman, Joel S. Finkelstein	153
2	Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer 2008 ·Urology ·Matthew Smith, Hang Lee, Mary Anne Fallon, David M. Nathan	93
3	Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer 2007 ·Journal of Clinical Oncology ·M. Dror Michaelson, Donald S. Kaufman, Hang Lee, Francis J. McGovern, Philip W. Kantoff, Mary Anne Fallon, Joel S. Finkelstein, Matthew R. Smith	235
4	High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma 2004 ·Cancer ·Michael J. Morris, Òren Smaletz, David B. Solit, William Kevin Kelly, Susan F. Slovin, Carlos D. Flombaum, Tracy Curley, A. Delacruz, Lawrence Schwartz, Martin Fleisher, Andrew X. Zhu, (unknown), Mary Anne Fallon, Howard I. Scher	30
5	Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial 2004 ·The Journal of Clinical Endocrinology & Metabolism ·Matthew Smith, Mary Anne Fallon, Hang Lee, Joel S. Finkelstein	182
6	Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer 2003 ·Urology ·Matthew R. Smith, Mary Anne Fallon, (unknown)	38
7	Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. 2003 ·PubMed ·William Kevin Kelly, Andrew X. Zhu, Howard I. Scher, (unknown), Mary Anne Fallon, Susan F. Slovin, Lawrence H. Schwartz, Steven M. Larson, William P. Tong, Beryl Hartley‐Asp, Cinzia Pellizzoni, Maurizio Rocchetti	14
8	Measurement of body fat by dual-energy x-ray absorptiometry and bioimpedance analysis in men with prostate cancer 2002 ·Nutrition ·Matthew R. Smith, (unknown), Ellen J. Anderson, Mary Anne Fallon, Judith Manola	10
9	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer breakdown → 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Matthew R. Smith, Joel S. Finkelstein, Francis J. McGovern, Anthony L. Zietman, Mary Anne Fallon, David Schoenfeld, Philip W. Kantoff	520
10	Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer breakdown → 2001 ·New England Journal of Medicine ·Matthew R. Smith, Francis J. McGovern, Anthony L. Zietman, Mary Anne Fallon, Ivor S. Douglas, David Schoenfeld, Philip W. Kantoff, Joel S. Finkelstein	542
11	Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men¹ 2001 ·The Journal of Clinical Endocrinology & Metabolism ·Benjamin Z. Leder, Matthew R. Smith, Mary Anne Fallon, Mei‐Ling Ting Lee, Joel S. Finkelstein	49
12	Low bone mineral density in hormone-na�ve men with prostate carcinoma 2001 ·Cancer ·Matthew R. Smith, Francis J. McGovern, Mary Anne Fallon, David Schoenfeld, Philip W. Kantoff, Joel S. Finkelstein	119
13	Low bone mineral density in hormone‐naïve men with prostate carcinoma 2001 ·Cancer ·Matthew R. Smith, Francis J. McGovern, Mary Anne Fallon, David Schoenfeld, Philip W. Kantoff, Joel S. Finkelstein	3
14	The bisphosphonate 2-PEBP inhibits cyclosporin A induced high-turnover osteopenia in the rat. 1990 ·PubMed ·Colin Movsowitz, Sol Epstein, Mary Anne Fallon, (unknown), S. Thomas	17
15	The Frequency of Apnea and Bradycardia in a Population of Healthy, Normal Infants 1983 ·Neuropediatrics ·Israel M. Stein, Mary Anne Fallon, (unknown), Joseph L. Kennedy	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact